1. Home
  2. NFGC vs ACRS Comparison

NFGC vs ACRS Comparison

Compare NFGC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Found Gold Corp

NFGC

New Found Gold Corp

HOLD

Current Price

$1.50

Market Cap

760.5M

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.55

Market Cap

608.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFGC
ACRS
Founded
2016
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
760.5M
608.9M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
NFGC
ACRS
Price
$1.50
$5.55
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$10.20
AVG Volume (30 Days)
1.7M
2.0M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
$3,542.00
N/A
Revenue Next Year
$118.57
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$1.46
52 Week High
$3.59
$5.85

Technical Indicators

Market Signals
Indicator
NFGC
ACRS
Relative Strength Index (RSI) 39.44 65.27
Support Level $1.45 $4.13
Resistance Level $2.12 N/A
Average True Range (ATR) 0.08 0.31
MACD 0.01 0.06
Stochastic Oscillator 18.64 77.41

Price Performance

Historical Comparison
NFGC
ACRS

About NFGC New Found Gold Corp

New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Companies exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: